The impact of the salting-out technique on the preparation of colloidal particulate systems for pharmaceutical applications

Recent Patents on Drug Delivery and Formulation

Volumn 6, Issue 3, 2012, Pages 236-249

  Mendoza Muñoz, Néstor ^a   Quintanar Guerrero, David ^a   Allémann, Eric ^b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Colloids; Drug delivery; Nanocapsules; Nanospheres; Polymers; Salting out

Indexed keywords

BETA ESCIN; CELECOXIB; CELLACEFATE; DEXAMETHASONE; EUDRAGIT; EUDRAGIT E100; IBUPROFEN; INSULIN; KANAMYCIN; LATEX; MACROGOL; MAGNESIUM ACETATE; MAGNESIUM CHLORIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; MONOCLONAL ANTIBODY HER2; NANOPARTICLE; PACLITAXEL; POLOXAMER; POLYCAPROLACTONE; POLYGLACTIN; POLYGLYCOLIC ACID; POLYLACTIC ACID; POLYMER; POLYMETHACRYLIC ACID; POLYSORBATE 80; POLYVINYL ACETATE; POLYVINYL ALCOHOL; RAPAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERTEPORFIN;

ARTICLE; BIODEGRADABILITY; CELL TRANSPORT; CELL VIABILITY; COLLOID; DISPERSION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SYNTHESIS; FREEZE DRYING; HUMAN; HYDROPHILICITY; NANOEMULSION; NANOENCAPSULATION; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PATENT; PRIORITY JOURNAL; PROCESS OPTIMIZATION;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; COLLOIDS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NANOMEDICINE; NANOPARTICLES; PATENTS AS TOPIC; POLYMERS;

EID: 84867833019     PISSN: 18722113     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221112802652688     Document Type: Article

References (73)

1. Vikdjerg, A., Petersen, S., Melander, F., Henriksen, J., Jorgensen, K. Liposomes for drug delivery. EP2123258A1 (2009).
2. Fologea, D., Salamo, G., Henry, R., Borrelli, M., Corry, P. Method of controlled drug release form a liposome carrier. WO2010114901A1 (2010).
3. Neuberger, W., Albrecht, V. Pegylated liposomes formulations for photodynamic treatment of inflammatory diseases. US20110160642A1 (2011).
4. Zhu, T., Szostak, J. Uniform-sized, multi-drug carrying, and photosensitive liposomes for advanced drug delivery. US20110105995A1 (2011).
5. Alcantar, N., Williams, E., Toomey, R. Niosome-hydrogel drug delivery system. US20100068264A1 (2010).
6. Breitenkamp, K., Sill, K., Skaff, H., Breitenkamp, R. Compositions comprising polymeric micelles for drug delivery. US20110091534A1 (2011).
7. Legen, I., Kerc, J., Jurkovic, P. Self-microemulsifying drug delivery systems. (2010).
8. Paleos, C., Tsiourvas, D., Sideratou, O. Multifunctional dendrimers and hyperbranched polymers as drug and gene delivery sytems. US20060204472A1 (2006).
9. Chung, B., Lim, Y., Kim, K. Gold nanocages containing magnetic nanoparticles. US20100228237A1 (2010).
10. Cheon, J., Lee, J.-H. Nanoparticles for penetration of blood-brain barrier. WO2009136763A2 (2009).
11. Viladot, P.J., Delgado, G.R., Fernández, B.A. Lipid nanoparticle capsules. WO2011116963A2 (2011).
12. Mishra B, Patel BB, Tiwari S. Colloidal nanocarriers: A review on formulation technology, types and applications toward targeted drug delivery. Nanomed: Nanotechnol, Biol Medicine 2010; 6 (1): 9-24.
13. Muthu M. Nanoparticles based on PLGA and its co-polymer: An overview. Asian J Pharmaceut 2009; 3 (4): 266-73.
14. Quintanar-Guerrero D, Allémann E, Fessi H, Doelker E. Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind Pharm 1998; 24 (12): 1113-28.
15. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surfac B: Biointerfac 2010; 75 (1): 1-18.
16. Maeda H, Matsumura Y. EPR effect based drug design and clinical outlook for enhanced cancer chemotherapy. Adv Drug Deliv Rev 2010;
17. Ourique AF, Pohlmann AR, Guterres SS, Beck RCR. Tretinoinloaded nanocapsules: Preparation, physicochemical characterization, and photostability study. Int J Pharm 2008; 352 (1-2): 1-4.
18. Vanderhoff, J.W., El-Aasser, M.S., Ugelstad, J. Polymeric emulsification process. US4177177 (1979).
19. Fessi, H., Devissaguet, J.-P., Puisieux, F., Thies, C. Procédé de préparation de systèmes colloidaux dispersibles d'une substance, sous forme du nanoparticules. EP0275796A1 (1988).
20. Bindschaedler, C., Gurny, R., Doelker, E. Process for preparing a powder of water-insoluble polymer wich can be redispersed in a liquid phase, the resulting powder and utilization therof. WO8808011 (1988).
21. Quintanar-Guerrero, D., Allémann, E., Gurny, R., Fessi, H., Doelker, E. Method for producing an aqueous colloidal dispersion of nanoparticles. WO9933558A1 (1999).
22. Quintanar, D., Fessi, H., Doelker, E., Allémann, E. Method for preparing vesicular nanocapsules. WO9904766A1 (1999).
23. Quintanar-Guerrero, D., Allémann, E., Gurny, R., Fessi, H., Doelker, E. Method for producing aqueous colloidal dispersions of nanoparticles. WO0102087A1 (2001).
24. Zambaux MF, Bonneaux F, Gref R, Maincent P, Dellacherie E, Alonso MJ, Labrude P, Vigneron C. Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. J Controlled Release 1998; 50 (1-3): 31-40.
25. Bindschaedler, C., Gurny, R., Doelker, E. Process for preparing a powder of water-insoluble polymer wich can be redispersed in a liquid phase, the resulting powder and utilization thereof. US4968350 (1990).
26. Galindo-Rodriguez S, Allémann E, Fessi H, Doelker E. Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion, and nanoprecipitation methods. Pharm Res 2004; 21 (8): 1428-39.
27. Allémann E, Gurny R, Doelker E. Preparation of aqueous polymeric nanodispersions by a reversible salting-out process: Influence of process parameters on particle size. Int J Pharm 1992; 87 (1-3): 247-53.
28. Konan YN, Gurny R, Allémann E. Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles. Int J Pharm 2002; 233 (1-2): 239-52.
29. Zweers MLT, Grijpma DW, Engbers GHM, Feijen J. The preparation of monodisperse biodegradable polyester nanoparticles with a controlled size. J Biomed Mat Res Part B: App Biomat 2003; 66B (2): 559-66.
30. Galindo-Rodríguez S, Puel F, Briançon S, Allémann E, Doelker E, Fessi H. Comparative scale-up of three methods for producing ibuprofen-loaded nanoparticles. Eur J Pharm Sci 2005; 25 (4-5): 357-67.
31. Galindo-Rodríguez S, Allémann E, Doelker E, Fessi H. Verastility of three techniques for preparing ibuprofen-loaded methacrylic acid copolymer nanoparticles of controlled sizes. J Drug Deliv Sci Technol 2005; 15 (5): 347-54.
32. Song X, Zhao Y, Wu W, Bi Y, Cai Z, Chen Q, Li Y, Hou S. PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: Systematic study of particle size and drug entrapment efficiency. Int J Pharm 2008; 350 (1-2): 320-9.
33. Song XR, Cai Z, Zheng Y, He G, Cui FY, Gong DQ, Hou SX, Xiong SJ, Lei XJ, Wei YQ. Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur J Pharm Sci 2009; 37 (3-4): 300-5.
34. Allémann E, Leroux JC, Gurny R, Doelker E. In vitro extendedrelease properties of drug-loaded poly(DL-lactic acid) nanoparticles produced by a salting-out procedure. Pharm Res 1993; 10 (12): 1732-7.
35. Allémann E, Leroux JC, Gurny R, Doelker E. In vitro extendedrelease properties of drug-loaded poly(DL-lactic acid) nanoparticles produced by a salting-out procedure. Pharm Res 1993; 10 (12): 1732-7.
36. Leroux J-C, Allémann E, De Jaeghere F, Doelker E, Gurny R. Biodegradable nanoparticles-From sustained release formulations to improved site specific drug delivery. J Controlled Release 1996; 39 (2-3): 339-50.
37. Allémann E, Brasseur N, Benrezzak O, Rousseau J, Kudrevich SV, Boyle RW, Leroux J-C, Gurny R, Van Lier JE. PEG-coated Poly(lactic acid) nanoparticles for the delivery of hexadecafluoro zinc phthalocyanine to EMT-6 mouse mammary tumours. J Pharm Pharmacol 1995; 47 (5): 382-7.
38. De Jaeghere F, Allémann E, Leroux J-C, Stevels W, Feijen J, Doelker E, et al. Formulation and lyoprotection of poly(lactic acidco-ethylene oxide) nanoparticles: Influence on physical stability and in vitro cell uptake. Pharm Res 1999; 16 (6): 859-66.
39. De Jaeghere F, Allémann E, Feijen J, Kissel T, Doelker E, Gurny R. Freeze-Drying and lyopreservation of diblock and triblock poly(lactic acid-poly(ethylene oxide) (PLA-PEO) copolymer nanoparticles. Pharm Dev Technol 2000; 5 (4): 473-83.
40. Zweers ML, Engbers GH, Grijpma DW, Feijen J. Release of antirestenosis drugs from poly(ethylene oxide)-poly(DL-lactic-coglycolic acid) nanoparticles. J Controlled Release 2006; 114 (3): 317-24.
41. Zweers MLT, Engbers GHM, Grijpma DW, Feijen J. In vitro degradation of nanoparticles prepared from polymers based on dllactide, glycolide and poly(ethylene oxide). J Controlled Release 2004; 100 (3): 347-56.
42. Zhang Z, Grijpma DW, Feijen J. Poly(trimethylene carbonate) and monomethoxy poly(ethylene glycol)-block-poly(trimethylene carbonate) nanoparticles for the controlled release of dexamethasone. J Controlled Release 2006; 111 (3): 263-70.
43. Marouf W. Nanoparticle pharmaceutical carrier. WO2007132205A2 (2007).
44. Eley JG, Tirumalasetty PP. Release characteristics of polymethacrylate nanospheres containing coumarin-6. J Microencapsul 2003; 20 (5): 653.
45. Nguyen CA, Allémann E, Schwach G, Doelker E, Gurny R. Synthesis of a novel fluorescent poly(d, l-lactide) end-capped with 1-pyrenebutanol used for the preparation of nanoparticles. Eur J Pharm Sci 2003; 20 (2): 217-22.
46. Fay F, Quinn DJ, Gilmore BF, McCarron PA, Scott CJ. Gene delivery using dimethyldidodecylammonium bromide-coated PLGA nanoparticles. Biomaterials 2010; 31 (14): 4214-22.
47. Van de Ven H, Ludwig A, Vermeersch M, Vandenbroucke RE, Matheeussen A, Apers S, et al. Intracellular drug delivery in Leishmania-infected macrophages: evaluation of saponin-loaded PLGA nanoparticles. J Drug Target 2012; 20(2):142-54. Epub 2011 Nov 14
48. Van de Ven H, Vandervoort J, Weyenberg W, Apers S, Ludwig A. Mixture designs in the optimisation of PLGA nanoparticles: influence of organic phase composition on beta-aescin encapsulation. J Microencapsul 2012; 29(2):115-25. Epub 2011 Nov 2
49. Eley JG, Priyanka M. Preparation and release characteristics of insulin and insulin-like growth factor-one from polymer nanoparticles. J Microencapsul 2007; 24 (3): 225-34.
50. Nobs L, Buchegger F, Gurny R, Allémann E. Surface modification of poly(lactic acid) nanoparticles by covalent attachment of thiol groups by means of three methods. Int J Pharm 2003; 250 (2): 327-37.
51. Nobs L, Buchegger F, Gurny R, Allémann E. Biodegradable nanoparticles for direct or two-step tumor immunotargeting. Bioconjug Chem 2006; 17 (1): 139-45.
52. Cirstoiu-Hapca A, Bossy-Nobs L, Buchegger F, Gurny R, Delie F. Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles. Int J Pharm 2007; 331 (2): 190-6.
53. Cirstoiu-Hapca A, Buchegger F, Bossy L, Kosinski M, Gurny R, Delie F. Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells. Eur J Pharm Sci 2009; 38 (3): 230-7.
54. Allémann, E., Konan, Y., Gurny, R., Boch, R.E. Compositions and method for delivery of photosensitive drugs. WO03097096A1 (2003).
55. Allémann, E., Konan, Y., Gurny, R., Boch, R.E. Compositions and methods for delivery of photosensitive drugs. US7455858B2 (2008).
56. Allémann, E., Konan, Y., Gurny, R., Boch, R.E. Compositions and methods for delivery of photosensitive drugs. EP1503796B1 (2010).
57. Dolmans, D., Fukumura, D., Jain, R.K. Photodynamic therapy for cancer. Nat Rev Cancer 2003; 3 (5): 380-7.
58. Konan-Kouakou YN, Boch R, Gurny R, Allémann E. In vitro and in vivo activities of verteporfin-loaded nanoparticles. J Controlled Release 2005; 103 (1): 83-91.
59. Bender, H.-M., Haunschild, J., Wiesner, M., Lang, U., Friedlander, M. Methods and compositions for the treatment of diseases of the eye. WO0241910A2 (2002).
60. Bender, H.-M., Haunschild, J., Lang, U., Wiesner, M., Friedlander, M. Integrin inhibitors for the treatment of eye diseases. WO03013511A1 (2003).
61. Bender, H.-M., Haunschild, J., Lang, U., Wiesner, M., Friedlander, M. Methods and compositions for the treatment of diseases of eye. EP1381382B1 (2008).
62. Du Toit LC, Pillay V, Choonara YE, Iyuke SE. Formulation and evaluation of a salted-out isoniazid-loaded nanosystem. AAPS PharmSciTech 2008; 9 174-81.
63. Donnelly RF, Morrow DIJ, Fay F, Scott CJ, Abdelghany S, Singh RRT, Garland MJ, David Woolfson A. Microneedle-mediated intradermal nanoparticle delivery: Potential for enhanced local administration of hydrophobic pre-formed photosensitisers. Photodiagn Photodynam Therap 2010; 7 (4): 222-31.
64. Ibrahim H, Bindschaedler C, Doelker E, Buri P, Gurny R. Aqueous nanodispersions prepared by a salting-out process. Int J Pharm 1992; 87 (1-3): 239-46.
65. Perugini P, Simeoni S, Scalia S, Genta I, Modena T, Conti B, Pavanetto F. Effect of nanoparticle encapsulation on the photostability of the sunscreen agent, 2-ethylhexyl-pmethoxycinnamate. Int J Pharm 2002; 246 (1-2): 37-45.
66. Olvera-Martinez BI, Cazares-Delgadillo J, Calderilla-Fajardo SB, Villalobos-Garcia R, Ganem-Quintanar A, Quintanar-Guerrero D. Preparation of polymeric nanocapsules containing octyl methoxycinnamate by the emulsification-diffusion technique: penetration across the stratum corneum. J Pharm Sci 2005; 94 (7): 1552-9.
67. Eley JG, Pujari VD, McLane J. Poly (Lactide-co-Glycolide) nanoparticles containing coumarin-6 for suppository delivery: In vitro release profile and in vivo tissue distribution. Drug Deliv 2004; 11 (4): 255-61.
68. Wheatley, M.A., Lewandowski, J. Novel polymeric ultrasound contrast agent and methods of making thereof. US20090028797A1 (2009).
69. Wheatley, M.A., Lewandowski, J. Nano-sized ultrasound contrast agent: salting-out method. Mol Imaging 2010; 9 (2): 96-107.
70. Morawski AM, Lanza GA, Wickline SA. Targeted contrast agents for magnetic resonance imaging and ultrasound. Curr Opin Biotechnol 2005; 16 (1): 89-92.
71. Hilmann, J., Lange, L., Zimmermann, I. Mikropartikel und gasblächen enthaltendes ultraschall-kontrastmittel. EP0123235A2 (1984).
72. Lohrmann, R. Gas-filled microspheres with fluorine-containig shells. WO9604018A1 (1996).
73. Bender, H.-M., Lang, U., Wiesner, M., Friedlander, M. Methods and compositions for the treatment of eye diseases. WO03068253A1 (2003).